ZORA Ventures

ZORA Ventures, based in Tel Aviv, is an early-stage venture capital firm with an investment focus on health technology, bio-convergence, and sustainability. The thesis ties these areas together by treating modern health innovation as a problem of integrating biology, data, and technology, with sustainability as a constraint and an opportunity rather than as a separate vertical. For AI healthcare founders, the relevant zones include digital health, AI-driven diagnostics, clinical decision support, and bio-convergence platforms that combine biological data with software intelligence.

ZORA tends to back companies whose technology genuinely sits at an intersection. Pure SaaS without a scientific or biological angle, traditional consumer wellness, and conventional medical devices are not central. The fund favors companies where AI is the engine for new types of decisions, often using novel data sources such as multi-omics, imaging, sensor streams, or integrated clinical records, and where the path to differentiated outcomes is defensible.

Check sizes range from $1M to $5M, deployed at seed and Series A. ZORA participates as a lead or co-lead in priced rounds and reserves capital for follow-on. Geography is principally Israel, with companies expected to operate globally and commercialize primarily in the US and Europe. Syndicate relationships span Israeli, US, and European specialists in healthtech, AI, and life sciences, which is useful for companies that will need diverse capital sources as they scale.

The team carries a combination of investment, technical, and operational backgrounds, with thematic depth across the convergence areas the fund targets. Board engagement at the early stage tends to be active, with help focused on technical hiring, scientific advisory, regulatory pathway thinking, and downstream financing strategy.

Founders should approach ZORA with a clear articulation of why their company sits at the convergence of biology, technology, and a real-world outcome, and what kind of data or experimental advantage drives durable differentiation. Introductions through Israeli early-stage funds, US life science investors, or operators in the bio-convergence ecosystem are the highest-signal path in. The right moment to engage is when a credible team is assembled, a working prototype or early data exists, and the round is being structured. Founders pitching pure consumer wellness, generic enterprise SaaS, or traditional medical devices will not fit the thesis. Companies whose AI angle is decorative rather than substantive will struggle to clear diligence. For founders building real bio-convergence and AI-enabled health technology that requires a partner comfortable with the messiness of cross-disciplinary work, ZORA is one of the more thesis-coherent early-stage backers in Israel.